Risk factor
Very vulnerable to price shocks
Profitability factor
Very favourable analyst view
In Guru Portfolios
Portfolio Weight (%)
Change
Fund
Portfolio Weight (%)
Change
Fund
Portfolio Weight (%)
Change
Fund
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
About
Omnicell, Inc., founded in 1992 and headquartered in Mountain View, California (initially operating as Omnicell Technologies, Inc. until its name change in 2001), delivers advanced medication management technologies and patient adherence solutions. The company serves healthcare systems and pharmacies both domestically within the United States and globally. Its extensive portfolio of offerings includes: Clinical Workflow Automation: Omnicell provides automated solutions designed to streamline clinician tasks in patient care environments. This encompasses the XT Series automated dispensing units for medications and supplies across nursing units, clinical areas, and surgical suites. They also offer interface software to ensure smooth integration between their products and a healthcare facility's existing information systems, alongside robotic systems for automated storage and retrieval of packaged medications. Central Pharmacy Optimization: For the central pharmacy, Omnicell offers sophisticated automation, including automated storage and retrieval platforms like the XR2 Automated Central Pharmacy System. This segment also features robotic systems and workflow management tools for IV compounding, comprehensive inventory management software, and systems for controlled substance oversight. Single-Dose Packaging for Adherence: The company develops automated technologies for filling and labeling patient-specific, single-dose medication blister packaging according to prescriptions. This includes both fully and semi-automated equipment for institutional pharmacies to ensure precise packaging, along with blister card packaging and supplies aimed at improving medication adherence, particularly in non-acute care settings. Digital Patient Engagement: Omnicell further provides EnlivenHealth Patient Engagement, a web-based platform offering various tools to interact with patients.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV
Target Price
The average target price of OMCL is 64 and suggests 66.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa